SEC Form 4 · accession 0001562180-19-001422
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
III Frederick Beddingfield
Officer — President & CEO · Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2019 | P | 40,000 | $2.50 | A | 831,662 | D | |
| Common StockF2 | holding | — | — | — | 112,614 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's public offering at the offering price of $2.50 per share.
- F2The shares are directly held by the Beddingfield Family Trust.